We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

57 hedge funds and large institutions have $13.6M invested in Matinas BioPharma in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

4% more funds holding

Funds holding: 55 → 57 (+2)

0.01% less ownership

Funds ownership: 0.26% → 0.25% (-0.01%)

24% less capital invested

Capital invested by funds: $18M → $13.6M (-$4.38M)

Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$159K
2
SIG
Sargent Investment Group
Maryland
+$118K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$117K
4
GRP
Global Retirement Partners
California
+$92.5K
5
VF
Virtu Financial
New York
+$78.4K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.04M
2
BCM
Bridgeway Capital Management
Texas
-$66.5K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$63K
4
MA
MONECO Advisors
Connecticut
-$19K
5
GAA
Global Assets Advisory
Florida
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$26.1K +$20.8K +626 +150%
PAG
27
Private Advisor Group
New Jersey
$25K +$13.2K +396 +12%
JP Morgan Chase
28
JP Morgan Chase
New York
$23K – – –
ECM
29
ExodusPoint Capital Management
New York
$23K +$30.6K +920 New
NWMG
30
National Wealth Management Group
Ohio
$20.5K -$3.33K -100 -11%
AWS
31
Atria Wealth Solutions
New York
$19.7K – – –
Morgan Stanley
32
Morgan Stanley
New York
$19.5K +$12.7K +381 +96%
Goldman Sachs
33
Goldman Sachs
New York
$17.6K +$23.4K +704 New
Osaic Holdings
34
Osaic Holdings
Arizona
$17K – – –
DAS
35
Dynamic Advisor Solutions
Arizona
$15K – – –
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$14.5K +$19.3K +581 New
Commonwealth Equity Services
37
Commonwealth Equity Services
Massachusetts
$14K – – –
Victory Capital Management
38
Victory Capital Management
Texas
$11.8K – – –
RPC
39
Rossmore Private Capital
Connecticut
$8.75K – – –
TRCT
40
Tower Research Capital (TRC)
New York
$8K -$2.06K -62 -16%
CFG
41
Cooper Financial Group
California
$6.95K – – –
CG
42
Clarus Group
Texas
$6K – – –
UBS Group
43
UBS Group
Switzerland
$5.93K +$7.88K +237 New
JWCA
44
J.W. Cole Advisors
Florida
$5.38K – – –
MFG
45
Magnus Financial Group
New York
$5K -$3.33K -100 -33%
CFS
46
CRA Financial Services
New Jersey
$5K – – –
FAIM
47
Financial Advocates Investment Management
Washington
$5K – – –
SW
48
SlateStone Wealth
Florida
$5K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$4K -$233 -7 -4%
Wells Fargo
50
Wells Fargo
California
$3.28K -$9.58K -288 -69%
1
2
3

MTNB Hedge Fund Activity: Q4 2022 in Review

57 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2022, worth a combined $13.6M — down 24% from $18M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MTNB positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $159K. The largest seller was BlackRock, cutting an estimated $1.04M.

  • 57 institutional investors held Matinas BioPharma (MTNB) as of Q4 2022, up from 55 in Q3 2022.
  • Funds reported $13.6M of Matinas BioPharma stock for Q4 2022, down 24% quarter-over-quarter.
  • 9 funds opened new Matinas BioPharma positions in Q4 2022 and 6 closed out, a net change of +3 holders.
  • The largest Matinas BioPharma buyer in Q4 2022 was Millennium Management, an estimated $159K added.
  • The largest Matinas BioPharma seller in Q4 2022 was BlackRock, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2022.